Biomedical papers, 2010 (vol. 154), issue 4

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010, 154(4):321-326 | 10.5507/bp.2010.048

IDENTIFICATION OF CD133+/NESTIN+ PUTATIVE CANCER STEM CELLS IN NON-SMALL CELL LUNG CANCER

Maria Janikova*a,b, Jozef Skardaa,b, Marta Dziechciarkovac, Lenka Radovac, Jana Chmelovaa, Veronika Krejcia, Eva Sedlakovaa,b, Jana Zapletalovad, Katerina Langovad, Jiri Kleine, Ivona Grygarkovaf, Vitezslav Kolekf
a Department of Pathology and Laboratory of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
b Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital
c Department of Pediatrics, Laboratory of Experimental Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital
d Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University
e 1st Department of Surgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital
f Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and Dentistry, Palacky University and University Hospital

Aims: No effective treatment for lung cancer exists currently. One reason for this, is the development of drug resistance, assumed to be associated with cancer stem cell (CSCs) emergence within the tumour. This pilot study aimed to identify CSCs in 121 non-small cell lung cancer (NSCLC) patient samples via detection of the expression of stem cell markers - CD133 and nestin.

Material and methods: Archived paraffin blocks of 121 patient samples were prepared as Tissue Microarrays (TMA). Indirect immunohistochemical staining was used to determine the level of expression of CD133 and nestin. Double immunofluorescence staining was used to investigate the co-expression of these two markers. To determine the correlation between expression of nestin and CD133 with the length of asymptomatic period and overall patient survival we used the Kaplan-Meyer analysis.

Results: CD133 expression was detected in 22 (19%), nestin in the epithelium in 74 (66%) and vasculature in 78 (70%) of patients. Co-expression of these two markers was found in 21 (17%) patients in less than 1% of positive cells without impact on disease free or overall survival.

Conclusions: We identified CD133+/nestin+ cells as novel potential markers of lung cancer CSCs.

Keywords: CD133, Nestin, Non-small cell lung cancer (NSCLC), Cancer stem cell (CSC), Immunofluorescence

Received: May 26, 2010; Accepted: September 21, 2010; Published: December 1, 2010


References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:22549. Go to original source... Go to PubMed...
  2. Okamoto OK. Cancer stem cell genomics: the quest for early markers of malignant progression. Expert Rev Mol Diagn 2009;9:54554. Go to original source... Go to PubMed...
  3. Chiba T, Kamiya A, Yokosuka O, Iwama A. Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective. Cancer Lett 2009;286:14553. Go to original source... Go to PubMed...
  4. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:500212.
  5. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:58218. Go to PubMed...
  6. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007;20:1027. Go to original source... Go to PubMed...
  7. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004;57:9659. Go to original source... Go to PubMed...
  8. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007;6:927.
  9. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:254256. Go to original source... Go to PubMed...
  10. Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Ferrando U et al. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006;169:222335. Go to original source... Go to PubMed...
  11. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:10610. Go to original source... Go to PubMed...
  12. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:1094651. Go to original source... Go to PubMed...
  13. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008;214:39. Go to original source... Go to PubMed...
  14. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:75660. Go to original source... Go to PubMed...
  15. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133 metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:211120. Go to original source... Go to PubMed...
  16. Karbanova J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerová H et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 2008;56:97793. Go to original source... Go to PubMed...
  17. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 2008;27:85. Go to original source... Go to PubMed...
  18. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:50414. Go to original source... Go to PubMed...
  19. Rotondo F, Kovacs K, Horvath E, Bell CD, Lloyd RV, Scheithauer BW. Immunohistochemical expression of nestin in the non-tumorous hypophysis and in pituitary neoplasms. Acta Neuropathol 2006;111:2727. Go to original source... Go to PubMed...
  20. Yang XH, Wu QL, Yu XB, Xu CX, Ma BF, Zhang XM et al. Nestin expression in different tumours and its relevance to malignant grade. J Clin Pathol 2008;61:46773. Go to original source... Go to PubMed...
  21. Sugawara K, Kurihara H, Negishi M, Saito N, Nakazato Y, Sasaki T et al. Nestin as a marker for proliferative endothelium in gliomas. Lab Invest 2002;82:34551. Go to original source... Go to PubMed...
  22. Lobo MV, Arenas MI, Alonso FJ, Gomez G, Bazán E, Paíno CL et al. Nestin, a neuroectodermal stem cell marker molecule, is expressed in Leydig cells of the human testis and in some specific cell types from human testicular tumours. Cell Tissue Res 2004;316:36976. Go to original source... Go to PubMed...
  23. Ehrmann J, Kolar Z, Mokry J. Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 2005;58:2223. Go to original source... Go to PubMed...
  24. Lachenmayer A, Lichtenauer UD, Cox T, Schott M, Malendowicz LK, Goretzki PE et al. Nestin as a marker in the classification of adrenocortical tumors. Horm Metab Res 2009;41:397401. Go to original source... Go to PubMed...
  25. Brychtova S, Fiuraskova M, Brychta T, Hirnak J. The role of intermedial filament nestin in malignant melanoma progression. Cesk Patol 2005;41:1435. Go to PubMed...
  26. Messam CA, Hou J, Berman JW, Major EO. Analysis of the temporal expression of nestin in human fetal brain derived neuronal and glial progenitor cells. Brain Res Dev Brain Res 2002;134:8792. Go to original source... Go to PubMed...
  27. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press;2004.
  28. Casella GT, Bunge MB, Wood PM. Improved immunocytochemical identification of neural, endothelial, and inflammatory cell types in paraffin-embedded injured adult rat spinal cord. J Neurosci Methods 2004;139:111. Go to original source... Go to PubMed...
  29. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009;106:162816. Go to original source... Go to PubMed...
  30. Yamamoto A, Shofuda T, Islam MO, Nakamura Y, Yamasaki M, Okano H et al. ABCB1 is predominantly expressed in human fetal neural stem/progenitor cells at an early development stage. J Neurosci Res 2009;87:261523. Go to original source... Go to PubMed...
  31. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010;126:9508. Go to original source... Go to PubMed...
  32. Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K et al. Nestin expression in osteosarcomas and derivation of nestin/ CD133 positive osteosarcoma cell lines. BMC Cancer 2008;8:300. Go to original source... Go to PubMed...
  33. Mokry J, Cizkova D, Filip S, Ehrmann J, Osterreicher J, Kolar Z et al. Nestin expression by newly formed human blood vessels. Stem Cells Dev 2004;13:65864. Go to original source... Go to PubMed...
  34. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:6982. Go to original source... Go to PubMed...